A Michigan-based nonprofit is launching a program that aims to help people addicted to prescription opioids, a step toward addressing a public health crisis that has seen tens of thousands of Americans overdose.
The initiative is the work of MS Project, a nonprofit founded by the Rev. William Barber, the founder of the Michigan Black Church of Christ.
The Michigan-focused nonprofit has raised more than $3.5 million and is in the process of launching a pilot program for residents of the state to try the drug-reversing drug Narcan, a nasal spray that can reverse overdoses.
The program is intended to help address the opioid epidemic, Barber said.
The Narcan drug was developed by Purdue Pharma to treat patients who have used opioids for a long time and who have developed tolerance to the drug.
The drug is meant to help control the amount of opioids in the body, so patients can return to their daily lives.
Michigan-born Barber was raised in a predominantly black church in Detroit and began studying religious and civil rights issues at the University of Chicago.
He founded MS Project to provide an alternative to prescription painkillers, which he believes can help people with addiction.
MS Project is the latest effort to help addicts.
A group of medical professionals in New York City and Philadelphia have launched a program to treat addicts.
The Centers for Disease Control and Prevention estimates that 1.2 million Americans use opioids for pain relief every day.
More than 1.1 million Americans have died from the opioid overdose since 2014, according to the CDC.
Barber, who lives in Detroit, said the goal of the program is to provide a drug-free, socially-responsible alternative to opioid prescriptions, but not necessarily a drug.
Barber said he was initially skeptical about the program when it was announced in March.
“I had no idea that this would actually get done,” he said.
MS, which will initially be funded through donations and a grant from the National Institute on Drug Abuse, is partnering with the Michigan Department of Community Health and Social Services.
MS is also working with the American Academy of Addiction Medicine to develop a drug and treatment plan.
MS has also hired a team of pharmacists and trained more than 30 health professionals.
MS’s goal is to develop Narcan and other drugs for the state of Michigan and other states, including Illinois, which has a $1.5 billion opioid overdose crisis.
The plan is to launch a pilot state program later this year and then expand to other states and cities, Barber and other MS Project officials said.
They added that the plan is not meant to be a quick fix.
The goal is not to just create a drug that is going to save lives.
The idea is to do this as quickly as possible, and we’re not even there yet.
MS will use its own money to fund the pilot program.
MS says it has already used a grant to develop an opioid-specific treatment protocol, a medication that can treat opioid addiction.
It is currently developing a treatment protocol for patients with multiple chronic pain conditions and for those who have been taking opioids for more than two years.
The treatment protocol will include Narcan in the initial phase of the trial, and MS Project says it is also studying whether to create a new drug, a fentanyl-based drug that can be administered by a physician.
The FDA has approved a drug called Narcan for use in the treatment of opioid addiction, but the drug is not widely available.
MS said it has obtained FDA approval for its treatment protocol.
MS plans to open its first facility in Lansing to help with the trial.
MS officials said the pilot has not yet started and that they are still gathering data and analyzing the data.
MS President and CEO Scott Stedman said MS has spent more than five years studying how to use Narcan.
“Our goal is for MS to be able to deliver the drugs in a way that is safe, effective, and non-toxic,” Stedmen said.
He said the trial is meant for people who have tried other medications to treat pain and other ailments, including heroin and methadone.
MS believes that Narcan will not be the only treatment option available to those who are addicted to opioids.
MS hopes to develop other opioid-based medications, like Naloxone, which can be injected directly into the brain.
The Drug Enforcement Administration last year proposed a $10 billion program to help fight the opioid abuse epidemic.
The new program would be funded by an excise tax on opioid-related products and services, and would include $10 million to support research.
The proposed tax is aimed at encouraging manufacturers of opioids to manufacture more safe and effective medications for use by the opioid-addicted population.
MS and its partners plan to work with Michigan and the FDA to determine whether the new Narcan medication can be safely administered.
The company has also asked Michigan Gov.
Rick Snyder to sign a law that would allow the state health department to oversee the safety and efficacy of Narcan during the pilot phase of